Company intelligence / Profile preview
AI Therapeutics
Guilford, Connecticut, United Statesorphai-therapeutics.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 1
01
Overview
AIT-101 (apilimod), a PIKfyve kinase inhibitor, has demonstrated safety and a 73% reduction in toxic poly(gp) protein aggregates in Phase 2a ALS patients; plans for phase 2/3 are ongoing. Other historical programs included attempts in COVID-19 and oncology, but the focus has shifted to neurodegenerative and rare diseases.
- Therapeutic areas
- PulmonologyOncologyNeurologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on AI Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AI Therapeutics.